newsfilter
← Latest News
GlobeNewswire·

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

ARTL
  • Artelo Biosciences received a Notice of Allowance from the USPTO for a U.S. patent covering the intended commercial formulation of ART27.13.
  • The allowed claims protect ART27.13 compositions dispersed in polyethylene glycol & are expected to extend patent protection through 2041.
  • ART27.13 is a peripherally selective cannabinoid agonist currently in Phase 2 CAReS trials for cancer-related anorexia & Phase 2 DREAM studies for glaucoma or ocular hypertension.
  • Interim Phase 2 CAReS results showed that all patients on the highest dose of ART27.13 reversed cancer-related anorexia, while placebo participants continued to lose weight.
  • The DREAM study evaluates ART27.13 as a once-daily oral treatment to reduce intraocular pressure, with initial results anticipated in Q4 2026.
  • ART27.13 is a benzimidazole derivative & dual cannabinoid agonist developed initially by AstraZeneca that targets peripheral CB1 & CB2 receptors to minimize CNS toxicity.
  • In the CAReS trial, patients titrated to the highest dose achieved an average +6% weight gain over 12 weeks compared to a ~5% loss in the placebo group.
  • No FDA-approved treatments currently exist for cancer anorexia cachexia syndrome.
  • Artelo Biosciences focuses on developing proprietary therapeutics that modulate lipid-signaling pathways to address unmet needs in anorexia, cancer, pain, & other conditions.